参考文献/References:
[1] Jemal A, Bray F, Center MM, et al.Global cancer statistics[J].CA Cancer J Clin, 2011, 61(2):69-90.DOI:10.3322/caac.20107.
[2] 李鸣, 孙光, 贺大林, 等.前列腺癌诊断治疗指南[M].北京:人民卫生出版社, 2014:61-89.Li M, Sun G, He DL, et al.The guide of diagnosis and treatment of prostate cancer[M].Beijing:People’s Medical Publishing House, 2014:61-89.
[3] 姚林, 周利群.前列腺癌的间歇性内分泌治疗[J].中华外科杂志, 2011, 49(2):176-179.Yao L, Zhou LQ.The intermittent endocrine therapy of prostate cancer[J].Chin J Surg, 2011, 49(2):176-179.
[4] Ghafoori M, Velayati M, Aliyari Ghasabeh M, et al.Prostate Biopsy Using Transrectal Ultrasonography; The Optimal Number of Cores Regarding Cancer Detection Rate and Complications[J/OL].Iran J Radiol, 2015, 12(2):e13257[2016-05-01].http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4457971.DOI:10.5812/iranjradiol.13257.
[5] Gillies RJ, Robey I, Gatenby RA.Causes and consequences of increased glucose metabolism of cancers[J].J Nucl Med, 2008, 49 Suppl 2:S24-42.DOI:10.2967/jnumed.107.047258.
[6] Macheda ML, Rogers S, Best JD.Molecular and cellular regulation of glucose transporter(GLUT) proteins in cancer[J].J Cell Physiol, 2005, 202(3):654-662.
[7] Effert P, Beniers AJ, Tamimi Y, et al.Expression of glucose transporter 1(Glut-1) in cell lines and clinical specimens from human prostate adenocarcinoma[J].Anticancer Res, 2004, 24(5A):3057-3063.
[8] Stewart GD, Gray K, Pennington CJ, et al.Analysis of hypoxia-associated gene expression in prostate cancer:lysyl oxidase and glucose transporter-1 expression correlate with Gleason score[J].Oncol Rep, 2008, 20(6):1561-1567.
[9] 吴敏, 赵红光, 李英华, 等.PET-CT在前列腺癌诊断中的应用现状和展望[J].中国实验诊断学, 2015, 19(3):513-516.Wu M, Zhao HG, Li YH, et al.The present state and perspectives of PET-CT in the diagnosis of prostate cancer[J].Chin J Lab Diagn, 2015, 19(3):513-516.
[10] Liu IJ, Zafar MB, Lai YH, et al.Fluorodeoxyglucose positron emission tomography studies in diagnosis and staging of clinically organ-confined prostate cancer[J].Urology, 2001, 57(1):108-111.
[11] von Mallek D, Backhaus B, Müller SC, et al.Technical limits of PET/CT with 18FDG in prostate cancer[J].Aktuelle Urol, 2006, 37(3):218-221.DOI:10.1055/s-2006-932129.
[12] Watanabe H, Kanematsu M, Kondo H, et al.Preoperative detection of prostate cancer:a comparison with 11C-choline PET, 18F-fluorodeoxyglucose PET and MR imaging[J].J Magn Reson Imaging, 2010, 31(5):1151-1156.DOI:10.1002/jmri.22157.
[13] Fricke E, Machtens S, Hofmann M, et al.Positron emission tomography with 11C-acetate and 18F-FDG in prostate cancer patients[J].Eur J Nucl Med Mol Imaging, 2003, 30(4):607-611.DOI:10.1007/s00259-002-1104-y.
[14] Minamimoto R, Uemura H, Sano F, et al.The potential of FDG-PET/CT for detecting prostate cancer in patients with an elevated serum PSA level[J].Ann Nucl Med, 2011, 25(1):21-27.DOI:10.1007/s12149-010-0424-4.
[15] 王治国, 郭佳, 石庆学, 等.18F-FDG PET/CT在前列腺癌诊断中的应用价值[J].临床军医杂志, 2014, 42(4):409-411.DOI:10.3969/j.issn.1671-3826.2014.04.26.Wang ZG, Guo J, Shi QX, et al.Value of 18F-FDG PET/CT in diagnosis of prostate cancer[J].Clin J Med Offic, 2014, 42(4):409-411.
[16] Brown AM, Lindenberg ML, Sankineni S, et al.Does focal incidental F-FDG PET/CT uptake in the prostate have significance?[J].Abdom Imaging, 2015, 40(8):3222-3229.DOI:10.1007/s00261-015-0520-y.
[17] Beauregard JM, Blouin AC, Fradet V, et al.FDG-PET/CT for pre-operative staging and prognostic stratification of patients with high-grade prostate cancer at biopsy[J/OL].Cancer Imaging, 2015, 15:2[2016-05-01].http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4352558.DOI:10.1186/s40644-015-0038-0.
[18] Jadvar H.Molecular imaging of prostate cancer with 18F-fluorodeoxyglucose PET[J].Nat Rev Urol, 2009, 6(6):317-323.
[19] Jadvar H.Prostate cancer:PET with 18F-FDG, 18F- or 11C-acetate, and 18F- or 11C-choline[J].J Nucl Med, 2011, 52(1):81-89.DOI:10.2967/jnumed.110.077941.
[20] 陈雯, 姚稚明, 张建飞, 等.同期18F-FDG PET/CT 及 MRI 对于前列腺癌的初步对照研究[J].临床和实验医学杂志, 2015, 14(18):1491-1494.DOI:10.3969/j.issn.1671-4695.2015.18.002.Chen W, Yao ZM, Zhang JF, et al.A primary comparative study of the concurrent 18F-FDG PET/CT and MRI for the prostate cancer[J].J Clin Exp Med, 2015, 14(18):1491-1494.
[21] 李杨, 齐琳, 叶慧.18F-脱氧葡萄糖正电子发射计算机断层显像CT检查在前列腺癌诊断和分期中的应用价值[J].中华泌尿外科杂志, 2011, 32(10):682-684.DOI:10.3760/cma.j.issn.1000-6702.2011.10.013.Li Y, Qi L, Ye H.Applications value of 18F-FDG PET/CT in the diagnosis and staging of prostate cancer[J].Chin J Urol, 2011, 32(10):682-684.
[22] Hillner BE, Siegel BA, Shields AF, et al.Relationship between cancer type and impact of PET and PET/CT on intended management:findings of the national oncologic PET registry[J].J Nucl Med, 2008, 49(12):1928-1935.DOI:10.2967/jnumed.108.056713.
[23] Oyama N, Akino H, Suzuki Y, et al.FDG PET for evaluating the change of glucose metabolism in prostate cancer after androgen ablation[J].Nucl Med Commun, 2001, 22(9):963-969.
[24] Oyama N, Akino H, Suzuki Y, et al.Prognostic value of 2-deoxy-2-[F-18]fluoro-D-glucose positron emission tomography imaging for patients with prostate cancer[J].Mol Imaging Biol, 2002, 4(1):99-104.
[25] Meirelles GS, Schöder H, Ravizzini GC, et al.Prognostic value of baseline [18F]fluorodeoxyglucose positron emission tomography and 99mTc-MDP bone scan in progressing metastatic prostate cancer[J].Clin Cancer Res, 2010, 16(24):6093-6099.DOI:10.1158/1078-0432.CCR-10-1357.
[26] Jadvar H, Desai B, Ji L, et al,.Baseline 18F-FDG PET/CT parameters as imaging biomarkers of overall survival in castrate-resistant metastatic prostate cancer[J].J Nucl Med, 2013, 54(8):1195-1201.DOI:10.2967/jnumed.112.114116.
[27] Zukotynski KA, Kim CK, Gerbaudo VH, et al.18F-FDG-PET/CT and 18F-NaF-PET/CT in men with castrate-resistant prostate cancer[J].Am J Nucl Med Mol Imaging, 2015, 5(1):72-82.
[28] Yu CY, Desai B, Ji L, et al.Comparative performance of PET tracers in biochemical recurrence of prostate cancer:a critical analysis of literature[J].Am J Nucl Med Mol Imaging, 2014, 4(6):580-601.
[29] Mapelli P, Panebianco V, Picchio M.Prostate cancer recurrence:can PSA guide imaging?[J].Eur J Nucl Med Mol Imaging, 2015, 42(12):1781-1783.DOI:10.1007/s00259-015-3091-9.
[30] Chang CH, Wu HC, Tsai JJ, et al.Detecting metastatic pelvic lymph nodes by 18F-2-deoxyglucose positron emission tomography in patients with prostate-specific antigen relapse after treatment for localized prostate cancer[J].Urol Int, 2003, 70(4):311-315.DOI:10.1159/000070141.
[31] Schöder H, Herrmann K, Gönen M, et al.2-[18F] fluoro-2-deoxyglucose positron emission tomography for the detection of disease in patients with prostate-specific antigen relapse after radical prostatectomy[J].Clin Cancer Res, 2005, 11(13):4761-4769.
[32] Jadvar H, Desai B, Ji L, et al.Prospective evaluation of 18F-NaF and 18F-FDG PET/CT in detection of occult metastatic disease in biochemical recurrence of prostate cancer[J].Clin Nucl Med, 2012, 37(7):637-643.DOI:10.1097/RLU.0b013e318252d829.
[33] 徐慧琴, 薛杨央, 赵学峰, 等.18F-FDG PET-CT诊断前列腺癌复发与转移的价值[J].国际放射医学核医学杂志, 2011, 35(2):81-84.DOI:10.3760/cma.j.issn.1673-4114.2011.02.004.Xu HQ, Xue YY, Zhao XF, et al.Value of 18F-FDG PET-CT in diagnoss of prostate cancer recurrence and metastasis[J].Int J Radiat Med Nucl Med, 2011, 35(2):81-84.
[34] Pillarsetty N, Punzalan B, Larson SM.2-18F-Fluoropropionic acid as a PET imaging agent for prostate cancer[J].J Nucl Med, 2009, 50(10):1709-1714.DOI:10.2967/jnumed.109.064212.
[35] Castellucci P, Jadvar H.PET/CT in prostate cancer:non-choline radiopharmaceuticals[J].Q J Nucl Med Mol Imaging, 2012, 56(4):367-374.
[36] Yu CY, Desai B, Ji L, et al.Comparative performance of PET tracers in biochemical recurrence of prostate cancer:a critical analysis of literature[J].Am J Nucl Med Mol Imaging, 2014, 4(6):580-601.
[37] Meirelles GS, Schöder H, Ravizzini GC, et al.Prognostic value of baseline [18F]fluorodeoxyglucose positron emission tomography and 99mTc-MDP bone scan in progressing metastatic prostate cancer[J].Clin Cancer Res, 2010, 16(24):6093-6099.DOI:10.1158/1078-0432.CCR-10-1357.
相似文献/References:
[1]何燕,苏晋,郑晓霞,等.P-糖蛋白抑制剂在PET显像中的应用研究[J].国际放射医学核医学杂志,2016,40(1):1.[doi:10.3760/cma.j.issn.1673-4114.2016.01.001]
He Yan,Su Jin,ZhengXiaoxia,et al.Developing P-glycoprotein inhibitor marked by PET[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(4):1.[doi:10.3760/cma.j.issn.1673-4114.2016.01.001]
[2]许飞,刘建军,黄钢,等.PET乏氧显像在预测肿瘤乏氧及指导临床治疗中的应用进展[J].国际放射医学核医学杂志,2016,40(1):35.[doi:10.3760/cma.j.issn.1673-4114.2016.01.008]
Xu Fei,Liu Jianjun,Huang Gang,et al.The application of hypoxia imaging with PET in predicting tumor hypoxia and guiding clinical therapy[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(4):35.[doi:10.3760/cma.j.issn.1673-4114.2016.01.008]
[3]胡伟,赵军.小胶质细胞在AD炎性机制中的作用及其常见PET显像剂的应用进展[J].国际放射医学核医学杂志,2016,40(1):44.[doi:10.3760/cma.j.issn.1673-4114.2016.01.009]
Hu Wei,Zhao Jun.Microglia’s Alzheimer disease inflammatory mechanisms and progress of its common application in PET imaging agents[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(4):44.[doi:10.3760/cma.j.issn.1673-4114.2016.01.009]
[4]张莹莹,王振光,孔艳.PET/CT显像在肺间质纤维化中的应用进展[J].国际放射医学核医学杂志,2016,40(1):55.[doi:10.3760/cma.j.issn.1673-4114.2016.01.011]
Zhang Yingying,Wang Zhenguang,Kong Yan.Application advancement on PET/CT in pulmonary interstitial fibrosis[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(4):55.[doi:10.3760/cma.j.issn.1673-4114.2016.01.011]
[5]李海峰,张晓军,李云钢,等.国产模块LOOP环改良法合成11C-蛋氨酸[J].国际放射医学核医学杂志,2016,40(2):106.[doi:10.3760/cma.j.issn.1673-4114.2016.02.004]
Li Haifeng,Zhang Xiaojun,Li Yungang,et al.Synthesis of 11C-methionine on home-made module by the improved LOOP method[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(4):106.[doi:10.3760/cma.j.issn.1673-4114.2016.02.004]
[6]史文杰,孟召伟,谭建.基于Deauville标准探讨18F-FDG PET/CT在霍奇金淋巴瘤复发诊断中的应用价值[J].国际放射医学核医学杂志,2016,40(2):120.[doi:10.3760/cma.j.issn.1673-4114.2016.02.007]
Shi Wenjie,Meng Zhaowei,Tan Jian.Value of 18F-FDG PET/CT on diagnosis of Hodgkin lymphoma recurrence using Deauville criterion[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(4):120.[doi:10.3760/cma.j.issn.1673-4114.2016.02.007]
[7]李海峰,张晓军,张锦明.多巴胺转运蛋白显像剂11C-β-CFT在帕金森病中的应用研究[J].国际放射医学核医学杂志,2016,40(3):218.[doi:10.3760/cma.j.issn.1673-4114.2016.03.011]
Li Haifeng,Zhang Xiaojun,Zhang Jinming.Review of the use of dopamine transporter imaging agent 11C-β-CFT for diagnosing Parkinson disease[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(4):218.[doi:10.3760/cma.j.issn.1673-4114.2016.03.011]
[8]尤阳,轩昂,张杰,等.淋巴瘤患者大脑静息葡萄糖代谢改变[J].国际放射医学核医学杂志,2016,40(4):255.[doi:10.3760/cma.j.issn.1673-4114.2016.04.003]
You Yang,Xuan Ang,Zhang Jie,et al.Changes in resting-state brain glucose metabolism in patients with lymphoma[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(4):255.[doi:10.3760/cma.j.issn.1673-4114.2016.04.003]
[9]李菲,黄俊星,张俊.18F-FDG PET/CT在食管癌中的临床应用[J].国际放射医学核医学杂志,2016,40(4):282.[doi:10.3760/cma.j.issn.1673-4114.2016.04.009]
Li Fei,Huang Junxing,Zhang Jun.The clinical application of 18F-FDG PET/CT in esophageal cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(4):282.[doi:10.3760/cma.j.issn.1673-4114.2016.04.009]
[10]张巍,杨珂.18f正电子放射性药物生产及使用中医务人员的受照剂量研究[J].国际放射医学核医学杂志,2015,39(5):420.[doi:10. 3760 / cma. j. issn. 1673-4114. 2015. 05. 016]
zhang wei,yang ke..the research of radiation dose of 18f-fdg to pet/ct related personnel[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(4):420.[doi:10. 3760 / cma. j. issn. 1673-4114. 2015. 05. 016]
[11]廖光星,冷志欣,肖国有.前列腺癌骨转移影像诊断方法研究进展[J].国际放射医学核医学杂志,2016,40(6):464.[doi:10.3760/cma.j.issn.1673-4114.2016.06.012]
Liao Guangxing,Leng Zhixin,Xiao Guoyou.Progress of imaging in the diagnosis of bone metastases of prostate cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(4):464.[doi:10.3760/cma.j.issn.1673-4114.2016.06.012]
[12]徐慧琴,薛杨央,赵学峰,等.18F-FDG PET-CT诊断前列腺癌复发与转移的价值[J].国际放射医学核医学杂志,2011,35(2):81.[doi:10.3760/cma.j.issn.1673-4114.2011.02.004]
XU Hui-qin,XUE Yang-yang,ZHAO Xue-feng,et al.Value of 18F-FDG PET-CT in diagnoss of prostate cancer recurrence and metastasis[J].International Journal of Radiation Medicine and Nuclear Medicine,2011,35(4):81.[doi:10.3760/cma.j.issn.1673-4114.2011.02.004]
[13]高骏,段玉清,于江,等.新型PET显像剂18F-FACBC在前列腺癌中的应用进展[J].国际放射医学核医学杂志,2017,41(4):288.[doi:10.3760/cma.j.issn.1673-4114.2017.04.010]
Gao Jun,Duan Yuqing,Yu Jiang,et al.Application of new PET imaging agent 18F-FACBC in prostate cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2017,41(4):288.[doi:10.3760/cma.j.issn.1673-4114.2017.04.010]